Have a feature idea you'd love to see implemented? Let us know!

VIRX Viracta Therapeutics Inc

Price (delayed)

$0.156

Market cap

$6.2M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.1

Enterprise value

$9.98M

Viracta is a precision oncology company targeting virus-associated malignancies. The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination ...

Highlights
The company's debt fell by 34% YoY and by 10% QoQ
VIRX's EPS is up by 11% YoY and by 5% from the previous quarter
The equity has plunged by 122% YoY
The quick ratio has dropped by 57% year-on-year and by 30% since the previous quarter

Key stats

What are the main financial stats of VIRX
Market
Shares outstanding
39.74M
Market cap
$6.2M
Enterprise value
$9.98M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$40.11M
EBITDA
-$39.67M
Free cash flow
-$34.8M
Per share
EPS
-$1.1
Free cash flow per share
-$0.88
Book value per share
-$0.17
Revenue per share
$0
TBVPS
$0.55
Balance sheet
Total assets
$21.96M
Total liabilities
$28.58M
Debt
$16.91M
Equity
-$6.62M
Working capital
-$6.77M
Liquidity
Debt to equity
-2.56
Current ratio
0.76
Quick ratio
0.74
Net debt/EBITDA
-0.1
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-114.4%
Return on equity
-680.3%
Return on invested capital
-296.5%
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VIRX stock price

How has the Viracta Therapeutics stock price performed over time
Intraday
-14.43%
1 week
5.48%
1 month
-20.41%
1 year
-69.65%
YTD
-72.63%
QTD
-32.58%

Financial performance

How have Viracta Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$47.21M
Net income
-$43.29M
Gross margin
N/A
Net margin
N/A
The net income has grown by 9% YoY and by 4.5% from the previous quarter
The operating income is up by 4.6% since the previous quarter and by 3.1% year-on-year

Growth

What is Viracta Therapeutics's growth rate over time

Valuation

What is Viracta Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VIRX's EPS is up by 11% YoY and by 5% from the previous quarter
The equity has plunged by 122% YoY

Efficiency

How efficient is Viracta Therapeutics business performance
The ROE has plunged by 133% from the previous quarter
The return on assets has dropped by 95% year-on-year and by 24% since the previous quarter
The return on invested capital has dropped by 76% since the previous quarter

Dividends

What is VIRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VIRX.

Financial health

How did Viracta Therapeutics financials performed over time
The company's total assets is 23% lower than its total liabilities
The company's total assets has shrunk by 67% YoY and by 30% QoQ
The quick ratio has dropped by 57% year-on-year and by 30% since the previous quarter
Viracta Therapeutics's debt to equity has shrunk by 136% QoQ
The equity has plunged by 122% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.